EUVIMEDEUVIMED entdecken
Open Access

Genetics versus clinical risk scores for melanoma prediction

Huanwei Wang iD, Hadis Ghajari, G J M Shanika R Jayasinghe, Mathias Seviiri iD, Scott D Gordon, Rachel E Neale, Nirmala Pandeya iD, Catherine M Olsen iD, Stuart MacGregor iD, David C Whiteman iD, Matthew H Law iD

British Journal of Dermatology · 2026

DOI: 10.1093/bjd/ljag126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2026. Verfasst von Huanwei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genetics & Skin Cancer Group, Population Health Program, QIMR Berghofer, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: an NHMRC Investigator, Australian Skin and Skin Cancer Research Centre, Cancer Council Queensland Next Generation Research Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cutaneous melanoma is a common cancer, for which risk stratification has been proposed to aid early detection.

Objectives

To assess the performance of a polygenic risk score (PRS) in predicting the risk of invasive cutaneous melanoma, alone and combined with clinical risk factors.

Methods

The PRS was derived from the most recent genome-wide association study meta-analysis of cutaneous melanoma, which included 28 849 patients with melanoma and 78 922 control participants from 20 studies from the UK, the USA, Australia and Europe. Then, it was tuned in the Canadian Longitudinal Studying on Aging cohort, which included 528 patients with melanoma and 17 787 control participants. The PRS was then tested independently against 14 self-reported clinical factors and a clinical prediction model (the MP16 model) in the QSkin prospective cohort, which included 16 282 participants with genetic data aged 40–69 years at baseline, among whom 359 were identified with new invasive melanomas during 10 years of follow-up.

Results

The PRS outperformed any other single clinical risk factor in QSkin (c-index 0.643). The baseline risk model (age, sex, first 10 principal components) had a c-index of 0.603; adding PRS to the baseline model increased the c-index to 0.670 [likelihood ratio test (LRT) P = 1.68 × 10–21]. Adding PRS to the MP16 model significantly enhanced discrimination [MP16 c-index: 0.713; MP16 + PRS c-index: 0.729 (median LRT P = 5.56 × 10–11)] and predicted more true cases in the first and second top deciles (111 for MP16 + PRS vs. 104 for MP16 in the first decile, and 72 for MP16 + PRS vs. 63 for MP16 in the second decile). Across various screening thresholds (10–50%), the sensitivity and/or specificity is higher and the net reclassification improvements were in the range of 0.01–0.05, comparing the MP16 + PRS model with the MP16 model.

Conclusions

Incorporating genetic risk information into existing clinical risk tools significantly improves prediction performance for melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansGenetic Risk ScoreMiddle AgedAgedFemaleGenome-Wide Association StudyMaleAdultRisk AssessmentGenetic Predisposition to DiseaseRisk Factors

Autor:innen und Institutionen

  • Genetics & Skin Cancer Group, Population Health Program, QIMR Berghofer, Brisbane, QLD, Australia.
  • Statistical Genetics Group, Population Health Program, QIMR Berghofer, Brisbane, QLD, Australia.
  • School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
  • School of Biomedical Sciences, Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, QLD, Australia.
  • Genetic Epidemiology Group, Brain and Mental Health Program, QIMR Berghofer, Brisbane, QLD, Australia.
  • Cancer Aetiology & Prevention Group, Population Health Program, QIMR Berghofer, Brisbane, QLD, Australia.

ORCID-Profile: Huanwei Wang, Mathias Seviiri, Nirmala Pandeya, Catherine M Olsen, Stuart MacGregor, David C Whiteman, Matthew H Law

Förderung

  • an NHMRC Investigator
  • Australian Skin and Skin Cancer Research Centre
  • Cancer Council Queensland Next Generation Research Fellowship
  • Government of Canada
  • CIHR
  • Canada Foundation for Innovation
  • Canadian Institutes of Health Research

Zitieren

APA

Wang, H., Ghajari, H., Jayasinghe, G. J. M. S. R., Seviiri, M., Gordon, S. D., Neale, R. E., Pandeya, N., Olsen, C. M., MacGregor, S., Whiteman, D. C., & Law, M. H. (2026). Genetics versus clinical risk scores for melanoma prediction. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljag126

Vancouver

Wang H, Ghajari H, Jayasinghe GJMSR, Seviiri M, Gordon SD, Neale RE, et al. Genetics versus clinical risk scores for melanoma prediction. British Journal of Dermatology. 2026. doi:10.1093/bjd/ljag126

BibTeX
@article{Wang2026,
  author = {Wang, Huanwei and Ghajari, Hadis and Jayasinghe, G J M Shanika R and Seviiri, Mathias and Gordon, Scott D and Neale, Rachel E and Pandeya, Nirmala and Olsen, Catherine M and MacGregor, Stuart and Whiteman, David C and Law, Matthew H},
  title = {Genetics versus clinical risk scores for melanoma prediction},
  journal = {British Journal of Dermatology},
  year = {2026},
  doi = {10.1093/bjd/ljag126}
}
Kostenlos starten →